ZyVersa Therapeutics
ZVSA

$2.51

10.36%

Market Cap: $2.58M

About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0.28% less ownership

Funds ownership: 1.5% [Q1] → 1.23% (-0.28%) [Q2]

50% less funds holding

Funds holding: 8 [Q1] → 4 (-4) [Q2]

54% less capital invested

Capital invested by funds: $84.9K [Q1] → $38.7K (-$46.1K) [Q2]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ZVSA.

See Analyst Rankings

Financial journalist opinion

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which is characterized by deposition of insoluble amyloid fibrils in tissues and organs disrupting their structure and function. Extracellular ASC interacts with serum amyloid A (SAA) released by the liver during inflammation, forming a scaffold that accelerates SAA aggregation into amyloid fibrils, which are deposited in tissues and organs.

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated ASC levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (NI) compared to ASC levels in those who: Were cognitively normal at both baseline and 1 year later (NN), and Were cognitively impaired at both baseline and one year later (II) Inflammasome-induced neuroinflammation has been associated with early stages of cognitive decline in dementia associated with Alzheimer's and Parkinson's diseases. Excessive inflammasome activation leads to cell death (pyroptosis) and systemic release of cell contents, including ASC that can be measured in the plasma.

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that obesity and its related metabolic complications has been selected as the lead indication for Inflammasome ASC Inhibitor IC 100.

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to restored retinal function. Retinopathy of Prematurity (ROP), affecting very low birth weight premature infants is a leading cause of childhood blindness worldwide.

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of obesity and its associated metabolic complications, among other inflammatory diseases. Mr. Glover welcomes one-on-one meetings with registered participants.

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024. GLP toxicology studies for Inflammasome ASC Inhibitor IC 100 scheduled to begin H1-2024, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation Q1-2025.Atherosclerosis preclinical data readout for Inflammasome ASC Inhibitor IC 100 on schedule for H1-2024.

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease

NLRP1 & pyrin govern inflammation in Alzheimer's Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

See News Rankings